Please use this identifier to cite or link to this item:
Type: Artigo de periódico
Title: Skin and oral lesions associated to imatinib mesylate therapy
Author: BASSO, Fernanda Goncalves
BOER, Camila Cominato
CORREA, Maria Elvira Pizzigatti
CINTRA, Maria Leticia
MAGALHAES, Marina H. C. Gallottini de
SANTOS, Paulo da Silva
SOUZA, Carmino Antonio de
Abstract: Imatinib mesylate is a tyrosine kinase inhibitor used to treat chronic myeloid leukemia (CML) throughout all the phases of the disease. In most cases, this drug is well tolerated; however, some cases experience side effects. Skin rashes and oral lesions are uncommon and appear to be dose-dependent. The authors report two cases of CML Ph(+) in chronic phase patients who presented skin and oral lesions probably induced by imatinib therapy.
Subject: Imatinib mesylate
Oral lesions
Skin lesions
Side effects
Country: Estados Unidos
Citation: SUPPORTIVE CARE IN CANCER, v.17, n.4, p.465-468, 2009
Rights: fechado
Identifier DOI: 10.1007/s00520-008-0536-8
Date Issue: 2009
Appears in Collections:FCM - Artigos e Outros Documentos
HEMO - Artigos e Outros Documentos

Files in This Item:
File Description SizeFormat 
art_BASSO_Skin_and_oral_lesions_associated_to_imatinib_2009.pdfpublished version228.18 kBAdobe PDFView/Open

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.